Encouraging results of a number of studies about solanezumab are expected to be announced in Washington at the Alzheimer’s conference. The new Alzheimer’s drug will be revealed soon enough.
Scientists are set to reveal the new drug that may slow the Alzheimer’s disease down. It is believed that if the new drug is prescribed to patients in the early stages of the disease, the medication will be able to slow the condition down. The announcement made at the Alzheimer’s Association International conference from Washington would most likely be a crucial moment in the treatment of Alzheimer’s disease.
The director of research from the Alzheimer’s Research UK, Dr. Eric Karran said that the new medicine had a very meaningful benefit for individuals suffering from a mild form of the condition. However, he did add that he is not suggesting the new drug is able to cure the disease.
Karran said that the people who did not receive the drugs and who were given a placebo showed deterioration in their conditions, exactly as they anticipated. But the individuals who received the medicine showed a slower deterioration in the disease by around 30 percent. When the scientists analyzed the two groups they saw an obvious difference between the people who were given the drug and the people who did not receive the drug.
Karran said that the people who were given the drug didn’t show as much deterioration in the condition. He also added that this was the first moment in which the scientists saw a benefit that looked surprisingly real and capable of modifying the disease. Karran is an ex-employee from Eli Lilly. Eli Lilly is the American pharmaceutical company responsible for the creation of the new drug.
Karran said that it might still be a number of years before the drug will be made available to NHS patients. He added that they are still waiting for the outcome from another phase three clinical trial that will happen in 2016. After this, the drug will have to be approved, a step that is incredibly important in the release. After this step, the launch of the medicine will depend on a talk with the NHS in order to find out if they believe that the new medicine has a relevant ratio of risk to benefit in order to be made accessible on the NHS.
Data shows that around 225,000 people will begin developing dementia in the United Kingdom this year. This means that the rate is one person every three minutes.
Image Source: worldhealthcareblog.org